Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 32Recurrence 8Neoplasms 6Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Smoldering Multiple Myeloma 1Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoma, Small Cell 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Cisplatin 3Pemetrexed 2Etoposide 2pomalidomide 1etoposide phosphate 1enzalutamide 1bemiparin 1apalutamide 1alvocidib 1abiraterone 1Radiation 1RRx-001 1Gemcitabine 1GSK2879552 1Depsipeptides 1Carboplatin 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Small Cell × pomalidomide × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡